Claims

1. A medium for neural stem cells and/or neural progenitor cells, comprising chelated iron, wherein a content of the chelated iron is 3 - 7 ppb.

2. The medium according to claim 1, which is for promoting proliferation of neural stem cells and/or neural progenitor cells.

3. The medium according to claim 1 or 2, which is for maintaining undifferentiation of neural stem cells and/or neural progenitor cells.

4. The medium according to any one of claims 1 to 3, wherein the neural stem cells and/or neural progenitor cells are derived from pluripotent stem cells.

5. A medium for inducing neural stem cells and/or neural progenitor cells, which comprises chelated iron, wherein a content of the chelated iron is 3 - 7 ppb.

6. The medium according to claim 5, which is for inducing neural stem cells and/or neural progenitor cells from pluripotent stem cells.

7. The medium according to any one of claims 1 to 6, wherein the chelated iron is bonded to an iron-binding protein.

8. The medium according to any one of claims 1 to 6, wherein the chelated iron is iron bonded to an iron chelating agent.

9. The medium according to any one of claims 1 to 6, wherein the chelated iron is iron bonded to at least one

kind selected from the group consisting of transferrin, lactoferrin, hemoglobin, ferritin, deferoxamine, citric acid, ethylenediaminetetraacetic acid (EDTA), phytic acid, nitrilotriacetic acid (NTA), diethylenetriaminepentaacetic acid (DTPA), glutamate diacetate (GLDA), hydroxyethylethylenediamineHydroxyethylethylenediamine triacetic acid (HEDTA), glycol etherdiaminetetraacetic acid (GEDTA), triethylenetetramine-N,N,N',N",N"',N"'-hexaacetic acid (TTHA), hydroxyethyliminodiacetic acid (HIDA), and dihydroxyethylglycine (DHEG).

10. The medium according to claim 9, wherein at least one kind of chelated iron is iron bonded to transferrin.

11. The medium according to claim 10, wherein a content of transferrin in the medium is not less than 0.5 μg/ml and not more than 6.5 μg/ml.

12. The medium according to claim 10, wherein a content of transferrin in the medium is not less than 0.1 μg/ml and not more than 1.8 μg/ml.

13. The medium according to claim 9, wherein at least one kind of chelated iron is iron bonded to deferoxamine, citric acid or ethylenediaminetetraacetic acid (EDTA).

14. The medium according to any one of claims 1 to 13, which is a serum-free medium.

15. The medium according to any one of claims 1 to 14, comprising a basic fibroblast growth factor (bFGF).

16. The medium according to claim 15, wherein an amount of bFGF in the medium is not less than 10 ng/ml and not more than 200 ng/ml.

17. A method of culturing neural stem cells and/or neural progenitor cells, comprising adding chelated iron to a medium, wherein a content of the chelated iron is 3 - 7 ppb.

18. A method of proliferating neural stem cells and/or neural progenitor cells, comprising adding chelated iron to a medium, wherein a content of the chelated iron is 3 - 7 ppb.

19. A method of maintaining undifferentiation of neural stem cells and/or neural progenitor cells, comprising adding chelated iron to a medium, wherein a content of the chelated iron is 3 - 7 ppb.

20. The method according to any one of claims 17 to 19, wherein the neural stem cells and/or neural progenitor cells are derived from pluripotent stem cells.

21. A method of inducing neural stem cells and/or neural progenitor cells, comprising adding chelated iron to a medium, wherein a content of the chelated iron is 3 - 7 ppb.

22. The method according to claim 21, which is for inducing neural stem cells and/or neural progenitor cells from pluripotent stem cells.

23. The method according to any one of claims 17 to 22, wherein the chelated iron is iron bonded to an iron-binding protein.

24. The method according to any one of claims 17 to 22, wherein the chelated iron is iron bonded to an iron chelating agent.

25. The medium according to any one of claims 17 to 22, wherein the chelated iron is iron bonded to at least one kind selected from the group consisting of transferrin, lactoferrin, hemoglobin, ferritin, deferoxamine, citric acid, ethylenediaminetetraacetic acid (EDTA), phytic acid, nitrilotriacetic acid (NTA), diethylenetriaminepentaacetic acid (DTPA), glutamate diacetate (GLDA), hydroxyethylethylenediamineHydroxyethylethylenediamine triacetic acid (HEDTA), glycol etherdiaminetetraacetic acid (GEDTA), triethylenetetramine-N,N,N′,N″,N‴,N‴′-hexaacetic acid (TTHA), hydroxyethyliminodiacetic acid (HIDA), and dihydroxyethylglycine (DHEG).

26. The method according to claim 25, wherein at least one kind of chelated iron is iron bonded to transferrin.

27. The method according to claim 26, wherein a content of transferrin in the medium is not less than 0.5 μg/ml and not more than 6.5 μg/ml.

28. The method according to claim 26, wherein a content of transferrin in the medium is not less than 0.1 μg/ml and not more than 1.8 μg/ml.

29. The method according to claim 25, wherein at least one kind of chelated iron is iron bonded to deferoxamine, citric acid or ethylenediaminetetraacetic acid (EDTA).

30. A culture composition comprising the medium according to any of claims 1 to 16 and neural stem cells and/or neural progenitor cells.